Compare RYAM & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | MDXG |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | United States | United States |
| Employees | 2325 | 808 |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.8M | 625.6M |
| IPO Year | 2014 | 2007 |
| Metric | RYAM | MDXG |
|---|---|---|
| Price | $8.44 | $4.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $9.00 |
| AVG Volume (30 Days) | 896.5K | ★ 1.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,466,397,000.00 | $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.22 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $3.35 | $3.03 |
| 52 Week High | $11.85 | $7.99 |
| Indicator | RYAM | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 56.99 |
| Support Level | $8.22 | $3.50 |
| Resistance Level | $8.80 | $4.45 |
| Average True Range (ATR) | 0.44 | 0.16 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 61.43 | 40.96 |
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.